Quetiapine Fumarate: A Review of Analytical Methods

Abstract

Atypical antipsychotics are newer second-generation antipsychotics with weak dopamine type 2 blocking but potent 5-HT2 antagonistic activity. They are considered first-line treatments for schizophrenia and gradually replace typical antipsychotics. Extrapyramidal side effects are minimal, and they tend to improve impaired cognitive function in psychotics. Quetiapine fumarate is an atypical antipsychotic drug used to treat schizophrenia, mania and depression in people with bipolar disorder combined with other drugs or alone. Quetiapine was developed in 1985 and approved for medical use in the USA in 1997. Thorough computer-aided literature, surveys revealed that numerous analytical methods were reported over the years. The present study reviews analytical methods with their validation parameters published during the last 22 years (1999–2021) either as a single entity or combination in dosage form, and determination from biological samples. Novel strategies for increasing separation quality, such as QbD analysis and green spectroscopy, were discovered during the evaluation, and this review can be utilized for further research reference.

Quetiapine-Related Deaths: In Search of a Surrogate Endpoint

“…Quetiapine is orally administered as a fumarate salt in the form of tablets. Daily doses in adults range from 150 to 750 mg, and steady-state concentrations are achieved within two days of dosing [ 59 ]. No specific plasma proteins that carry quetiapine were identified; however, it is converted into the active proteins and metabolites norquetiapine and 7-hydroxy quetiapine [ 60 , 61 ].…”